Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

AbbVie : Leukaemia patients to get access to AbbVies Venclyxto via Cancer Drugs Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:11pm CEST

The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England with chronic lymphocytic leukaemia (CLL), the common form of adult leukaemia via the CDF while it accrues more cost-effectiveness data.

Venclyxto will be available to adults with difficult-to-treat types of chronic lymphocytic leukaemia those patients without 17p deletion or TP53 mutation who have failed both chemo-immunotherapy and a B-cell receptor (BCR) inhibitor.

Venclyxto has also been recommended for the treatment of adult CLL patients in the presence of 17p deletion or TP53 mutation who are either unsuitable for or have failed a BCR inhibitor.

The decision represents a U-turn from NICE, which had rejected Venclyxto in first draft guidance published in February.

But since then AbbVie has been in talks with NICE and in final guidance, the cost-effectiveness watchdog granted interim funding from the CDF.

This will allow NICE to gather further evidence to address uncertainties in the dossier of trial evidence submitted by AbbVie, while giving CLL patients a further treatment option when other drugs have failed.

One concern cited by NICE was how generalisable the results of trials were to clinical practice in England, as neither the M12-175 nor M14-032 trials included any UK centres.

NICE also questioned evidence showing that despite having several therapies, CLL appeared not to have a detrimental effect on health-related quality of life of patients in the Venclyxto trials.

The committee concluded that patients in the trials were not as sick as those for whom the drug would be an option in England, meaning the treatment benefits in the population were uncertain.

Although data showed overall survival was much higher with Venclyxto, NICEs independent appraisal committee said the relative survival benefit compared with best supportive care was likely to be biased in favour of Venclexto.

Venclexto is likely to cost between 50,000-60,000 per Quality Adjusted Life Year gained, above the 30,000 threshold usually used by NICE but it has extra leeway as end of life criteria apply.

Dr Peter Hillmen, professor of Experimental Haematology and honorary consultant haematologist at Leeds Teaching Hospitals NHS Trust, said: Todays recommendation is great news for patients with CLL who have failed existing treatments, and provides clinicians with an important new treatment option.

The studies that NICE has assessed to reach this positive decision represent a milestone in the management of relapsed/refractory CLL.

The early clinical data is compelling, showing survival benefits for this challenging group of patients, including some who achieved complete remission. I would anticipate that collection of further data through the CDF will confirm these extremely promising early findings.

Alice Butler, medical director at AbbVie, said: Working together with the NHS to collect more long-term data provides an important opportunity to understand the impact of venetoclax on the survival of patients with this difficult-to-treat type of CLL.

Patients in Wales are likely to get access to drug in the coming months following NICEs ruling, while the Scottish Medicines Consortium already recommended funding in August in a separate decision.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
02:02pEISAI : AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injectio..
AQ
01:53pABBVIE : 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-An..
AQ
12:22pEISAI : AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injectio..
AQ
06/21ABBVIE : Announces U.S. FDA Approval of VENCLEXTA® venetoclax tablets in Combina..
AQ
06/21ABBVIE : Researchers at AbbVie Target Blood Cancer (Statins enhance efficacy of ..
AQ
06/21ABBVIE : Findings from AbbVie Provide New Insights into Drug Conjugates (Mechani..
AQ
06/21ABBVIE : Announces New Undetectable Minimal Residual Disease Data from Phase 3 R..
AQ
06/21Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug..
AC
06/20BRISTOL MYERS SQUIBB : Myers, AbbVie eye new use for myeloma drug Empliciti afte..
AQ
06/20ABBVIE : 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-An..
AQ
More news
News from SeekingAlpha
12:41aThe No. 1 Stock In The World (Redux) - Part 3 
06/211 High-Yield Blue Chip Set To Soar And 1 You Should Ignore 
06/1919 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks 
06/19DIVIDEND SENSEI'S PORTFOLIO UPDATE 3 : 3 Reasons You Should Avoid This Dangerous.. 
06/18Jane's May Dividend Income Tracker - Retirement Accounts 
Financials ($)
Sales 2018 32 922 M
EBIT 2018 14 384 M
Net income 2018 10 789 M
Debt 2018 28 636 M
Yield 2018 3,75%
P/E ratio 2018 13,89
P/E ratio 2019 12,44
EV / Sales 2018 5,61x
EV / Sales 2019 5,19x
Capitalization 156 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 114 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE1.59%155 911
MERCK KGAA-7.81%12 435
KYOWA HAKKO KIRIN CO LTD3.65%12 070
JAZZ PHARMACEUTICALS PLC36.04%11 043
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD71.34%10 038
CONVATEC GROUP8.52%5 622